Saga Pure ASA
Oslo, 10 January 2021
Reference is made to the stock exchange announcement on 30 December 2020 regarding information on three subsequent offerings in Saga Pure ASA ("Saga " or the "Company "). The board of directors of Saga has today, 10 January 2021, pursuant to the authorisation granted to it by the extraordinary general meeting held on 10 November 2020, resolved to increase the share capital by up to a total of NOK 137,000 through issuance of up to a total of 13,700,000 new shares, each with a par value of NOK 0.01, in connection with subsequent offerings in the Company.
The share capital increases have been resolved to carry out; (i) a subsequent offering following the private placement completed on 14 December 2020 ("Subsequent Offering I "), (ii) a subsequent offering following the private placement completed on 21 December 2020 ("Subsequent Offering II "), and (iii) a subsequent offering following the private placement completed on 29 December 2020 ("Subsequent Offering III " and together with Subsequent Offering I and Subsequent Offering II, the "Subsequent Offerings ").
The share capital increases are divided as following, (i) a share capital increase by up to NOK 40,000 in the Subsequent Offering I, through issuance of up to 4,000,000 new shares at a subscription price of NOK 2.10, (ii) a share capital increase by up to NOK 49,000 in the Subsequent Offering II, through issuance of up to 4,900,000 new shares at a subscription price of NOK 2.90, and (iii) a share capital increase by up to NOK 48,000 in the Subsequent Offering III, though issuance of up to 4,800,000 new shares at a subscription price of NOK 4.10.
The completion of the Subsequent Offerings is conditional upon the approval by the Financial Supervisory Authority of Norway of a prospectus and the publication of the same by the Company. The prospectus is expected to be approved during the week commencing 11 January 2020, and the subscription periods in the Subsequent Offerings will commence shortly thereafter. Further information will be provided in due course.
For additional information, please contact:
Bjørn Simonsen, CEO, +47 97 17 98 21
Espen Lundaas, CFO, +47 92 43 14 17
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S17.9.2025 23:05:02 CEST | Press release
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Biogen Inc.17.9.2025 22:30:05 CEST | Press release
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Atico Mining Corporation17.9.2025 22:30:00 CEST | Press release
Atico Signs the Investment Protection Agreement with Government of Ecuador for its La Plata Project
Frontline plc.17.9.2025 22:06:51 CEST | Press release
FRO – Filing of Half Yearly Report
VCI Global Limited17.9.2025 21:00:00 CEST | Press release
VCI Global Initiates Rescission and Cancellation of Shares from QuantGold Transaction, Tightening Capital Structure Following Reverse Split
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom